Indicators of inequity in research and funding for sickle cell disease, cystic fibrosis, and haemophilia: a descriptive comparative study
File(s)
Published version
Author(s)
Type
Journal Article
Abstract
Background
Sickle cell disease, one of the most common genetic conditions in the UK, is often considered a neglected disorder, but rigorous quantitative evidence to support this view is scarce. Comparative research of multiple conditions offers an effective way to document inequity and to guide public health policies. Therefore, we aimed to compare indicators of inequity in research and funding for sickle cell disease, cystic fibrosis, and haemophilia in the UK.
Methods
In this descriptive comparative study, we compiled publicly available data on disease prevalence for sickle cell disease, cystic fibrosis, and haemophilia, alongside seven comparative indicators: the number and value of grants from UK public health research funders (the Wellcome Trust, the National Institute for Health and Care Research, and UK Research and Innovation); resources available to dedicated charities (the Sickle Cell Society, the Cystic Fibrosis Trust, and the Haemophilia Society); characteristics of disease registries (the National Haemoglobinopathy Register, the UK Cystic Fibrosis Registry, and the UK National Haemophilia Database); the number of registered clinical trials (the National Library of Medicine Clinical Trials and the EU clinical trials register); number of scientific publications (PubMed); number of drug approvals (the Medicines and Healthcare products Regulatory Agency); and online disease awareness (Google Trends and Glimpse). We conducted descriptive analyses, including counts, proportions, means, and ratios.
Findings
We found marked differences in the seven indicators considered. Sickle cell disease was usually the most neglected condition, particularly when accounting for the number of people affected. The mean annual research funding per person was almost four times higher for cystic fibrosis (£704 [95% CI 697–710]) than for sickle cell disease (£184 [172–196]), and two times higher than for haemophilia (£315 [226–404]). There was one clinical trial per 273 people with sickle cell disease, compared with one trial per 53 and 55 people for cystic fibrosis and haemophilia, respectively. The mean annual number of publications was almost twice higher for cystic fibrosis (2431) than for sickle cell disease (1359) or haemophilia (1193).
Interpretation
The comparative evidence provided support the view that sickle cell disease is neglected compared with cystic fibrosis and haemophilia in relation to research and funding in the UK. The highest value for each indicator, often observed for cystic fibrosis, provides a benchmark target for the other two conditions. More dedicated research funding would likely have a ripple effect on other indicators, which could guide public health policies and have a major effect on the quality of life of people living with sickle cell disease.
Sickle cell disease, one of the most common genetic conditions in the UK, is often considered a neglected disorder, but rigorous quantitative evidence to support this view is scarce. Comparative research of multiple conditions offers an effective way to document inequity and to guide public health policies. Therefore, we aimed to compare indicators of inequity in research and funding for sickle cell disease, cystic fibrosis, and haemophilia in the UK.
Methods
In this descriptive comparative study, we compiled publicly available data on disease prevalence for sickle cell disease, cystic fibrosis, and haemophilia, alongside seven comparative indicators: the number and value of grants from UK public health research funders (the Wellcome Trust, the National Institute for Health and Care Research, and UK Research and Innovation); resources available to dedicated charities (the Sickle Cell Society, the Cystic Fibrosis Trust, and the Haemophilia Society); characteristics of disease registries (the National Haemoglobinopathy Register, the UK Cystic Fibrosis Registry, and the UK National Haemophilia Database); the number of registered clinical trials (the National Library of Medicine Clinical Trials and the EU clinical trials register); number of scientific publications (PubMed); number of drug approvals (the Medicines and Healthcare products Regulatory Agency); and online disease awareness (Google Trends and Glimpse). We conducted descriptive analyses, including counts, proportions, means, and ratios.
Findings
We found marked differences in the seven indicators considered. Sickle cell disease was usually the most neglected condition, particularly when accounting for the number of people affected. The mean annual research funding per person was almost four times higher for cystic fibrosis (£704 [95% CI 697–710]) than for sickle cell disease (£184 [172–196]), and two times higher than for haemophilia (£315 [226–404]). There was one clinical trial per 273 people with sickle cell disease, compared with one trial per 53 and 55 people for cystic fibrosis and haemophilia, respectively. The mean annual number of publications was almost twice higher for cystic fibrosis (2431) than for sickle cell disease (1359) or haemophilia (1193).
Interpretation
The comparative evidence provided support the view that sickle cell disease is neglected compared with cystic fibrosis and haemophilia in relation to research and funding in the UK. The highest value for each indicator, often observed for cystic fibrosis, provides a benchmark target for the other two conditions. More dedicated research funding would likely have a ripple effect on other indicators, which could guide public health policies and have a major effect on the quality of life of people living with sickle cell disease.
Date Issued
2025-10-01
Date Acceptance
2025-09-01
Citation
The Lancet Haematology, 2025, 12 (10), pp.e789-e797
ISSN
2352-3026
Publisher
Elsevier
Start Page
e789
End Page
e797
Journal / Book Title
The Lancet Haematology
Volume
12
Issue
10
Copyright Statement
Copyright © 2025 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
License URL
Identifier
https://www.ncbi.nlm.nih.gov/pubmed/40976242
PII: S2352-3026(25)00235-2
Subjects
Hematology
Life Sciences & Biomedicine
Science & Technology
Publication Status
Published
Coverage Spatial
England
Date Publish Online
2025-09-18